INBRX-106 HNSCC Combo Data Impressive but Ignored; Ozekibart BLA Still the Main Event

What happened

Inhibrx released updated Phase 2 data for INBRX-106 combined with Keytruda in head and neck squamous cell carcinoma, showing a 48.3% confirmed overall response rate, with particularly strong efficacy in HPV+ patients, but the stock barely moved. The market's focus remains squarely on ozekibart, the lead candidate, where a BLA submission is planned for Q2 2026 but faces persistent safety concerns related to hepatotoxicity. While the INBRX-106 data adds positive optionality, the company itself has guided that the program will not be interpretable until the second half of 2026, making this readout premature for underwriting. The muted reaction suggests investors are not yet willing to pay for a secondary asset that remains clinically immature. Overall, the story continues to be a single-asset regulatory bet with concentrated downside risk.

Implication

For investors, the INBRX-106 data is encouraging but does not alter the near-term thesis; the stock remains a binary bet on ozekibart's BLA submission and safety profile. The market's muted reaction signals that the current valuation already embeds high expectations for ozekibart success, leaving little room for additional upside from secondary programs. Any delay or negative regulatory feedback on ozekibart could overshadow the INBRX-106 progress. Meanwhile, the cash burn and pre-commercialization spending continue to pressure the balance sheet, increasing the cost of any misstep. We maintain our WAIT rating, with an attractive entry near $60 and a trim point above $95, as the risk/reward is skewed to the downside until the BLA is actually filed and accepted.

Thesis delta

The original thesis centered on ozekibart's BLA timeline and safety risk, with INBRX-106 as an immature optionality. The new HNSCC data adds a positive clinical signal for INBRX-106 but does not change the near-term risk profile; the program still lacks maturity and the company has guided that interpretability is 2H 2026. Therefore, the thesis remains essentially unchanged: WAIT until clearer filing-readiness signals or a better entry price, as the market is already crowded and pricing in a clean BLA path.